{
  "pmcid": "12514958",
  "sha256": "dc576661523c2ccccdb5dd2947adebaa0e3ae14c5034474def0731c8c82aebc0",
  "timestamp_utc": "2025-11-09T23:42:56.342437+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.477729112992272,
    "reading_ease": 32.413921604711106,
    "word_count": 286
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial of Tacrolimus Plus Prednisone in CIDP Management"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This retrospective cohort study was conducted at Xuanwu Hospital, Capital Medical University, from April 2019 to June 2023."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults diagnosed with CIDP according to the 2021 EAN/PNS guidelines, with an INCAT disability score ≥2."
      },
      "Intervention": {
        "score": 2,
        "evidence": "This study aimed to evaluate the efficacy and safety of tacrolimus plus prednisone (T&P) compared to prednisone monotherapy (PM) in CIDP maintenance treatment."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the efficacy and safety of tacrolimus plus prednisone (T&P) compared to prednisone monotherapy (PM) in CIDP maintenance treatment."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the response rate, defined as a ≥1-point improvement in INCAT score at 3, 6, and 12 months."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 74 screened patients, 34 were included (16 T&P, 18 PM)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 74 screened patients, 34 were included (16 T&P, 18 PM)."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The T&P group demonstrated significantly higher response rates at 3 and 6 months compared to PM, though this difference attenuated by 12 months."
      },
      "Harms": {
        "score": 1,
        "evidence": "Both groups showed comparable safety profiles, with no serious adverse reactions reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not applicable."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}